{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:40:18Z","timestamp":1775842818808,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-006379"],"award-info":[{"award-number":["INV-006379"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging mutations in SARS-CoV-2 cause several waves of COVID-19 pandemic. Here we investigate the infectivity and antigenicity of ten emerging SARS-CoV-2 variants\u2014B.1.1.298, B.1.1.7(Alpha), B.1.351(Beta), P.1(Gamma), P.2(Zeta), B.1.429(Epsilon), B.1.525(Eta), B.1.526-1(Iota), B.1.526-2(Iota), B.1.1.318\u2014and seven corresponding single amino acid mutations in the receptor-binding domain using SARS-CoV-2 pseudovirus. The results indicate that the pseudovirus of most of the SARS-CoV-2 variants (except B.1.1.298) display slightly increased infectivity in human and monkey cell lines, especially B.1.351, B.1.525 and B.1.526 in Calu-3 cells. The K417N\/T, N501Y, or E484K-carrying variants exhibit significantly increased abilities to infect mouse ACE2-overexpressing cells. The activities of furin, TMPRSS2, and cathepsin L are increased against most of the variants. RBD amino acid mutations comprising K417T\/N, L452R, Y453F, S477N, E484K, and N501Y cause significant immune escape from 11 of 13 monoclonal antibodies. However, the resistance to neutralization by convalescent serum or vaccines elicited serum is mainly caused by the E484K mutation. The convalescent serum from B.1.1.7- and B.1.351-infected patients neutralized the variants themselves better than other SARS-CoV-2 variants. Our study provides insights regarding therapeutic antibodies and vaccines, and highlights the importance of E484K mutation.<\/jats:p>","DOI":"10.1038\/s42003-021-02728-4","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:43:34Z","timestamp":1634147014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization"],"prefix":"10.1038","volume":"4","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3380-4473","authenticated-orcid":false,"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6481-4781","authenticated-orcid":false,"given":"Zhihai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-2317","authenticated-orcid":false,"given":"Xiaodong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-8889","authenticated-orcid":false,"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-5141","authenticated-orcid":false,"given":"Youchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"2728_CR1","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.cell.2021.04.006","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2523 (2021).","journal-title":"Cell"},{"key":"2728_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284\u20131294.e1289 (2020).","journal-title":"Cell"},{"key":"2728_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e819 (2020).","journal-title":"Cell"},{"key":"2728_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1126\/science.abe5901","volume":"371","author":"BB Oude Munnink","year":"2021","unstructured":"Oude Munnink, B. B. et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science 371, 172\u2013177 (2021).","journal-title":"Science"},{"key":"2728_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(20)30912-9","volume":"21","author":"M Koopmans","year":"2021","unstructured":"Koopmans, M. SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. Lancet Infect. Dis. 21, 18\u201319 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"2728_CR6","unstructured":"WHO. Weekly epidemiological update on COVID-19 - 13 April 2021. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---13-april-2021."},{"key":"2728_CR7","doi-asserted-by":"publisher","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, https:\/\/doi.org\/10.1126\/science.abg3055 (2021).","DOI":"10.1126\/science.abg3055"},{"key":"2728_CR8","doi-asserted-by":"publisher","unstructured":"Graham, M. S. et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health, https:\/\/doi.org\/10.1016\/S2468-2667(21)00055-4 (2021).","DOI":"10.1016\/S2468-2667(21)00055-4"},{"key":"2728_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","volume":"29","author":"X Shen","year":"2021","unstructured":"Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529\u2013539 (2021). e523.","journal-title":"Cell Host Microbe"},{"key":"2728_CR10","doi-asserted-by":"publisher","unstructured":"Li, Q. et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell, https:\/\/doi.org\/10.1016\/j.cell.2021.02.042 (2021).","DOI":"10.1016\/j.cell.2021.02.042"},{"key":"2728_CR11","doi-asserted-by":"publisher","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, https:\/\/doi.org\/10.1016\/j.cell.2021.02.037 (2021).","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"2728_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","volume":"397","author":"EC Sabino","year":"2021","unstructured":"Sabino, E. C. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 397, 452\u2013455, https:\/\/doi.org\/10.1016\/S0140-6736(21)00183-5 (2021).","journal-title":"Lancet"},{"key":"2728_CR13","doi-asserted-by":"crossref","unstructured":"Naveca, F., Nascimento, V., Souza, V., Corado, A. & Bello, G. COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1. (2021).","DOI":"10.21203\/rs.3.rs-275494\/v1"},{"key":"2728_CR14","doi-asserted-by":"publisher","unstructured":"Shen, X. et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. The New England journal of medicine, https:\/\/doi.org\/10.1056\/NEJMc2103740 (2021).","DOI":"10.1056\/NEJMc2103740"},{"key":"2728_CR15","doi-asserted-by":"publisher","unstructured":"Zhou, H. et al. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv, https:\/\/doi.org\/10.1101\/2021.03.24.436620 (2021).","DOI":"10.1101\/2021.03.24.436620"},{"key":"2728_CR16","doi-asserted-by":"publisher","unstructured":"McCallum, M. et al. SARS-CoV-2 immune evasion by variant B.1.427\/B.1.429. bioRxiv, https:\/\/doi.org\/10.1101\/2021.03.31.437925 (2021).","DOI":"10.1101\/2021.03.31.437925"},{"key":"2728_CR17","doi-asserted-by":"publisher","unstructured":"Annavajhala, M. K. et al. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv: the preprint server for health sciences, https:\/\/doi.org\/10.1101\/2021.02.23.21252259 (2021).","DOI":"10.1101\/2021.02.23.21252259"},{"key":"2728_CR18","unstructured":"Public, Health & England. SARS-CoV-2 variants of concern and variants under investigation in England. https:\/\/www.gov.uk\/government\/publications\/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201 (2021)."},{"key":"2728_CR19","doi-asserted-by":"publisher","unstructured":"Hogan, C. A. et al. Optimizing SARS-CoV-2 Variant of Concern Screening: Experience from British Columbia, Canada, Early 2021. 2021.2003.2023.21253520, https:\/\/doi.org\/10.1101\/2021.03.23.21253520 %J medRxiv (2021).","DOI":"10.1101\/2021.03.23.21253520"},{"key":"2728_CR20","doi-asserted-by":"publisher","unstructured":"Ikegame, S. et al. Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants. 2021.2003.2031.21254660, https:\/\/doi.org\/10.1101\/2021.03.31.21254660 %J medRxiv (2021).","DOI":"10.1101\/2021.03.31.21254660"},{"key":"2728_CR21","doi-asserted-by":"publisher","unstructured":"Bestle, D. et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 3, https:\/\/doi.org\/10.26508\/lsa.202000786 (2020).","DOI":"10.26508\/lsa.202000786"},{"key":"2728_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","volume":"6","author":"MM Zhao","year":"2021","unstructured":"Zhao, M. M. et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct. Target Ther. 6, 134 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2728_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"2728_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","volume":"29","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477\u2013488.e474 (2021).","journal-title":"Cell Host Microbe"},{"key":"2728_CR25","unstructured":"Wang et al. Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. Cell Discov, (2021)."},{"key":"2728_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384.e16 (2020).","journal-title":"Cell"},{"key":"2728_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"2728_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/CM9.0000000000001573","volume":"134","author":"HX Pan","year":"2021","unstructured":"Pan, H. X. et al. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin. Med. J. 134, 1289\u20131298 (2021).","journal-title":"Chin. Med. J."},{"key":"2728_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17972-1","volume":"11","author":"S Wu","year":"2020","unstructured":"Wu, S. et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 4081 (2020).","journal-title":"Nat. Commun."},{"key":"2728_CR30","doi-asserted-by":"publisher","unstructured":"Mansbach, R. A. et al. The SARS-CoV-2 Spike Variant D614G favors an open conformational state. bioRxiv, https:\/\/doi.org\/10.1101\/2020.07.26.219741 (2020).","DOI":"10.1101\/2020.07.26.219741"},{"key":"2728_CR31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310.e1220 (2020).","journal-title":"Cell"},{"key":"2728_CR32","unstructured":"Lassauni\u00e8re, R. et al. SARS-CoV-2 spike mutations arising in Danish mink and their spread to humans. https:\/\/files.ssi.dk\/Mink-cluster-5-short-report_AFO2 (2020)."},{"key":"2728_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-021-00617-0","volume":"6","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. Signal Transduct. Target Ther. 6, 196 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2728_CR34","doi-asserted-by":"publisher","unstructured":"Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell, https:\/\/doi.org\/10.1016\/j.cell.2021.04.025 (2021).","DOI":"10.1016\/j.cell.2021.04.025"},{"key":"2728_CR35","doi-asserted-by":"publisher","unstructured":"Lubinski, B., Tang, T., Daniel, S., Jaimes, J. A. & Whittaker, G. R. Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B.1.1.7: role of the P681H mutation. bioRxiv, https:\/\/doi.org\/10.1101\/2021.04.06.438731 (2021).","DOI":"10.1101\/2021.04.06.438731"},{"key":"2728_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-021-01554-8","volume":"18","author":"L Cheng","year":"2021","unstructured":"Cheng, L. et al. Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. Virol. J. 18, 87 (2021).","journal-title":"Virol. J."},{"key":"2728_CR37","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348\u20132361.e2346 (2021).","journal-title":"Cell"},{"key":"2728_CR38","doi-asserted-by":"publisher","unstructured":"Cao, Y. et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell research, 1\u201310, https:\/\/doi.org\/10.1038\/s41422-021-00514-9 (2021).","DOI":"10.1038\/s41422-021-00514-9"},{"key":"2728_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"2728_CR40","doi-asserted-by":"publisher","unstructured":"Truong, T. T. et al. Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. medRxiv: the preprint server for health sciences, https:\/\/doi.org\/10.1101\/2021.02.27.21252099 (2021).","DOI":"10.1101\/2021.02.27.21252099"},{"key":"2728_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281\u2013292.e286 (2020).","journal-title":"Cell"},{"key":"2728_CR42","doi-asserted-by":"publisher","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv, https:\/\/doi.org\/10.1101\/2021.01.14.426475 (2021).","DOI":"10.1101\/2021.01.14.426475"},{"key":"2728_CR43","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02728-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T19:46:03Z","timestamp":1670096763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02728-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2728"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-02728-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1196"}}